A Randomised, Double-Blind, Placebo Controlled, Parallel Group, Dose Ranging Study Evaluating the Efficacy and Safety of GW642444M Administered Once Daily Compared With Placebo for 28 Days in Adolescent and Adult Subjects With Persistent Asthma
Latest Information Update: 04 Jul 2023
Price :
$35 *
At a glance
- Drugs Vilanterol (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors GSK
- 06 May 2012 Planned number of patients changed from 594 to 600 as reported by European Clinical Trials Database record.
- 23 Feb 2012 Results published in the European Respiratory Journal.
- 18 May 2011 Results presented at the 107th International Conference of the American Thoracic Society.